Skip to main content
. Author manuscript; available in PMC: 2014 Nov 10.
Published in final edited form as: J Urol. 2010 Jul;184(1):74–80. doi: 10.1016/j.juro.2010.03.032

Table 2.

Univariate models for progression to invasive disease/radical cystectomy or to muscle-invasive disease/radical cystectomy in 155 patients (unless otherwise indicated)

Progression to invasive disease (≥cT1) or radical cystectomy Progression to muscle- invasive disease (≥cT2) or radical cystectomy
HR 95% CI P value HR 95% CI P value
Male 0.654 0.379, 1.13 0.13 0.698 0.389, 1.25 0.2
Age (per 10-yr increase) 1.02 0.827, 1.27 0.8 1.04 0.828, 1.31 0.7
Race (white non-Hispanic vs. all others) 0.810 0.328, 2.00 0.6 0.739 0.298, 1.83 0.5
Smoking history (n=146) 0.9 0.5
 None Ref Ref Ref Ref
 Current 0.860 0.351, 2.11 0.536 0.183, 1.57
 Former 1.02 0.629, 1.66 1.02 0.608, 1.71
Presenting symptoms 0.067 0.19
 Asymptomatic, micro-hematuria Ref Ref Ref Ref
 Gross hematuria 1.83 0.988, 3.38 1.89 0.986, 3.63
 Voiding symptoms (irritative or obstructive) 2.29 1.21, 4.32 1.94 0.975, 3.87
 Unknown 1.40 0.668, 2.91 1.36 0.621, 2.97
CIS pattern (n=120) 0.4 0.9
 Focal Ref Ref Ref Ref
 Multiple 1.05 0.626, 1.78 1.03 0.598, 1.79
 Diffuse 1.69 0.779, 3.66 1.25 0.527, 2.94
BCG responder (n=130)* 0.587 0.363, 0.947 0.029 0.532 0.320, 0.884 0.015
*

25 patients who progressed within 6 mo of BCG therapy or were not followed for 6 mo were excluded.